#USA #Orlando #ASH Annual Meeting #Foresight Diagnostics #PhasED-Seq

Foresight Diagnostics at the ASH Annual Meeting

Foresight Diagnostics, a frontrunner in ultrasensitive minimal residual disease (MRD) detection, is set to present several innovative studies at the forthcoming 67th American Society of Hematology (ASH) Annual Meeting. Scheduled from December 6 to 9, 2025, in Orlando, Florida, the presentations aim to highlight their pioneering PhasED-Seq™ technology, which is fundamentally altering the landscape of MRD analysis in lymphoma treatments.

The highlight of Foresight's contribution this year is the substantial shift towards utilizing circulating tumor DNA (ctDNA) in clinical trials, with a keen focus on hematologic malignancies. Not only is this technology enhancing retrospective assessments, but it is also being incorporated prospectively in MRD-guided trial designs and innovative therapeutic development programs.

Dr. David Kurtz, Chief Medical Officer and Co-founder of Foresight Diagnostics, remarked on this transformation within the field. He emphasized that the usage of ctDNA-MRD is transitioning from mere feasibility studies to being embedded within clinical trial frameworks. This evolution opens the door for molecular response analyses to directly influence patient care decisions, a pivotal advancement in the fight against lymphoma.

Foresight's current innovation, the Foresight CLARITY™ platform, represents a significant leap in the diagnosis and treatment of minimal residual disease. With its remarkable sensitivity, which can detect MRD in parts per million, this technology is set to furnish healthcare professionals and biopharmaceutical firms with crucial information, allowing for more personalized patient care strategies in both solid tumors and hematologic cancers.

Presentation Overview

Several key presentations will be delivered, showcasing the latest findings and advancements:

Saturday, December 6:

• - Response-adapted Phase 2 study of acalabrutinib prior to frontline chemotherapy for untreated large B-cell lymphoma, presented by Dr. Mark Roschewski (NCI/NIH) at 9:45-10:00 AM EST (Oral presentation).
• - First-in-human study of a novel CD30-directed antibody-drug conjugate, presented by Dr. Swetha Thiruvengadam (City of Hope) at 1:00-1:15 PM EST (Oral presentation).
• - Studies on genomic heterogeneity and treatment resistance in aggressive B-cell lymphomas by Dr. Jordan Goldstein (Stanford University) at 5:15-5:30 PM EST (Oral presentation).

Sunday, December 7:

• - Efficacy results of Golcadomide plus R-CHOP in untreated aggressive B-cell lymphoma presented by Dr. Grzegorz Nowakowski (Bristol Myers Squibb) at 9:45-10:00 AM EST (Oral presentation).
• - SMART STOP trial analysis presented by Dr. Jason Westin (MD Anderson Cancer Center) covering novel combinations for diffuse large B-cell lymphoma at 10:00-10:15 AM EST (Oral presentation).
• - Longitudinal ctDNA dynamics post-first-line therapy presented by Dr. Steven Wang (Stanford University) at 10:45-11:00 AM EST (Oral presentation).
• - Response-adapted treatments featuring mosunetuzumab presented by Dr. Ryan Lynch (Fred Hutch/University of Washington) from 6:00-8:00 PM EST (Poster).
• - A multicenter phase 2 study on pembrolizumab plus ctDNA-guided consolidation for Hodgkin lymphoma presented by Dr. Michael Randall (UCSF) from 6:00-8:00 PM EST (Poster).

Monday, December 8:

• - Precise-HL trial focusing on personalizing chemotherapy through ctDNA evaluation in advanced Hodgkin lymphoma presented by Dr. Ryan Lynch (Fred Hutch/University of Washington) from 6:00-8:00 PM EST (Poster).

Foresight Diagnostics is passionate about contributing to the MRD innovation landscape in lymphoma treatment and looks forward to the ASH Annual Meeting to share these vital insights and advancements with the medical community.

For those attending the conference, Foresight Diagnostics invites you to visit booth #2165 or reach out via email at [email protected] for further discussions and information about their leading-edge technology.

About Foresight Diagnostics

Foresight Diagnostics is not only a leader in cancer diagnostics but also a CLIA-registered laboratory committed to advancing patient care in oncology. The company's unique liquid biopsy platform, Foresight CLARITY™, offers unparalleled sensitivity in MRD detection, enabling actionable insights for patients suffering from both solid tumors and hematologic malignancies. For more information, visit foresight-dx.com and connect with Foresight on social platforms including X, LinkedIn, and Bluesky.